Loading clinical trials...
Loading clinical trials...
A Phase II Study of Irinotecan and Panitumumab as 3rd Line Treatment of Patients With Metastatic Colorectal Cancer Without KRAS Mutations
Conditions
Interventions
Irinotecan
Panitumumab
Locations
1
Denmark
Vejle Hospital, Dept. of Oncology
Vejle, Denmark
Start Date
November 1, 2008
Primary Completion Date
December 1, 2010
Completion Date
August 1, 2011
Last Updated
June 13, 2012
NCT04657068
NCT06625775
NCT06607458
NCT06820463
NCT07361003
NCT06792695
Lead Sponsor
Vejle Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions